I would love to go to a NANETS conference but I would need sponsorship or otherwise have to fund my own way there. Seattle sounds like a great place to visit. I would even have been their twitter correspondent had they asked!
I’ve been to the European equivalent twice, they always have theirs in Barcelona it would seem, at least NANETS uses different locations making it more interesting. It’s a scientific conference for the most part, but I guess some basic stuff is also covered.
However, in the world of instant contact and communications on the internet, together with twitter, one can keep up to speed on what is or has been discussed. One day, NANETS and ENETS will be sufficiently advanced that we can all watch the presentations from the comfort of our own homes (you heard it here!)
I’ve put together a collection of things I found interesting and offer them here for your perusal and selection via links.
One of the first issues to discuss was the confirmation of the new NANETS management team and board – you will recognise most names here:
Officers (2018 to 2020 Term):
- Chair: James Howe, MD The University of Iowa Carver College of Medicine
- Vice Chair: Emily Bergsland, MD The University of California San Francisco School of Medicine
- Secretary: Jonathan Strosberg, MD Moffitt Cancer Center
- Treasurer: Pam Kunz, MD Stanford University Medical Center
Board of Directors:
- Jennifer Chan, MD, MPH (2018-2020) Dana Farber Cancer Institute
- Thorvardur Halfdanarson, MD (2018-2020) The Mayo Clinic
- Daniel Halperin, MD (2015-2019) University of Texas MD Anderson Cancer Center
- Erik Nakakura, MD, Ph.D. Research Committee Board Representative (2018-2020) The University of California San Francisco School of Medicine
- Rodney Pommier, MD (2018-2020) Oregon Health and Science University
- Diane Reidy, MD (2015-2019) Memorial Sloan Kettering Cancer Center
- Simron Singh, MD, Conference Committee Board Representative (2018-2019) Odette Cancer Center at Sunnybrook Health Sciences Center
- Michael Soulen, MD (2018-2020) The Hospital of the University of Pennsylvania
- James Yao, MD (2018-2020) University of Texas MD Anderson Cancer Center
A selection of poster abstracts below. There was a lot more but these ones made output on twitter so I guess these were headline acts and probably of interest to patients. The extract texts/short videos I’ve included are probably all that most patients will need but when I have electronic access to the posters, I will update with links if possible and repost for those who would like to see the full detail.
This cover two posters, one for Neuroendocrine Carcinoma (very interesting) and the other covering Neuroendocrine Tumours (i.e. well differentiated NETs). Click on the title above or click here.
Some interesting snippets here and an indication that the most comprehensive Lung NET Guidelines are those produced by ENETS by Caplin et al. Click on the title above or click here.
Interesting summary of new stuff in trials. Plus some interesting bits on SI NETs and pNETs. Click on the title or click here. There’s also a short video of Dr Haldanasron (slightly different content) – click here.
Interesting trial output looking at the potential benefits of Lanreotide after Octreotide. Click on the title or click here.
Interesting and as with many specialist videos I’ve seen, sequencing of treatment remains challenging. Text and video inside. Click on the title to see more or click here.
As you will know from my staging and grading article, there is now a Grade 3 well differentiated tumour status (called a NET rather than a Neuroendocrine Carcinoma). However, there is not yet enough data to work out the optimum treatments, which may, in certain circumstances, be different from their poorly differentiated counterparts (Neuroendocrine Carcinoma). Click on the title above or click here.
An unmet need – very interesting text. Click on the title or click here.
Dr Soares discusses the two roles of Somatostatin analogs: treating symptoms related to the tumors and controlling tumor growth. Complete with video. Click on the title or click here.
Interesting data analysis about Lanreotide. Click on the title or click here.
Some very interesting stuff in here including comparisons with Octreotide. Click on the title or click here.
You may be prompted for a login, if so, let me know, I will post you the content. The ‘misses’ is mainly the fact that Keytruda (Pembrolizumab) does not look good as a single agent treatment for high grade NEC. Headline is “Pembrolizumab, though generally well tolerated, showed limited activity as a single agent in high-grade neuroendocrine neoplasms (NENs) in this study,” Arvind Dasari, MD, of MD Anderson Cancer Center in Houston, and colleagues concluded.” Some other interesting points though. Click on the title above or click here.
Thanks for reading
Please Share this post